OVID Quote, Financials, Valuation and Earnings

Cogent Biosciences, Inc. has a net margin of -9210.61% compared to Ovid Therapeutics, Inc.'s net margin of --. Ovid Therapeutics, Inc.'s return on equity of -59.7% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.

Ovid Therapeutics, Inc. has a consensus price target of $4.05, signalling upside risk potential of 153.06%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $50.75 which suggests that it could grow by 36.87%. Given that Ovid Therapeutics, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than Cogent Biosciences, Inc..

Ovid Therapeutics, Inc. has a beta of 0.254, which suggesting that the stock is 74.621% less volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.923%.

Ovid Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ovid Therapeutics, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Ovid Therapeutics, Inc. quarterly revenues are $132K, which are larger than Cogent Biosciences, Inc. quarterly revenues of --. Ovid Therapeutics, Inc.'s net income of -$12.2M is higher than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Ovid Therapeutics, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ovid Therapeutics, Inc. is 17.20x versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -9210.61% compared to Ovid Therapeutics, Inc.'s net margin of -82.06%. Ovid Therapeutics, Inc.'s return on equity of -59.7% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Ovid Therapeutics, Inc. has a consensus price target of $4.05, signalling upside risk potential of 153.06%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $91.13 which suggests that it could grow by 4.82%. Given that Ovid Therapeutics, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Ovid Therapeutics, Inc. has a beta of 0.254, which suggesting that the stock is 74.621% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.

Ovid Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ovid Therapeutics, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ovid Therapeutics, Inc. quarterly revenues are $132K, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Ovid Therapeutics, Inc.'s net income of -$12.2M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Ovid Therapeutics, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ovid Therapeutics, Inc. is 17.20x versus 14.73x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lyell Immunopharma, Inc. has a net margin of -9210.61% compared to Ovid Therapeutics, Inc.'s net margin of -258973.33%. Ovid Therapeutics, Inc.'s return on equity of -59.7% beat Lyell Immunopharma, Inc.'s return on equity of -86.7%.

Ovid Therapeutics, Inc. has a consensus price target of $4.05, signalling upside risk potential of 153.06%. On the other hand Lyell Immunopharma, Inc. has an analysts' consensus of $29.67 which suggests that it could grow by 30.63%. Given that Ovid Therapeutics, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than Lyell Immunopharma, Inc..

Ovid Therapeutics, Inc. has a beta of 0.254, which suggesting that the stock is 74.621% less volatile than S&P 500. In comparison Lyell Immunopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ovid Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lyell Immunopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ovid Therapeutics, Inc. pays -- of its earnings as a dividend. Lyell Immunopharma, Inc. pays out -- of its earnings as a dividend.

Ovid Therapeutics, Inc. quarterly revenues are $132K, which are larger than Lyell Immunopharma, Inc. quarterly revenues of $15K. Ovid Therapeutics, Inc.'s net income of -$12.2M is higher than Lyell Immunopharma, Inc.'s net income of -$38.8M. Notably, Ovid Therapeutics, Inc.'s price-to-earnings ratio is -- while Lyell Immunopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ovid Therapeutics, Inc. is 17.20x versus 82,351.11x for Lyell Immunopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences, Inc. has a net margin of -9210.61% compared to Ovid Therapeutics, Inc.'s net margin of --. Ovid Therapeutics, Inc.'s return on equity of -59.7% beat Cassava Sciences, Inc.'s return on equity of -86.98%.

Ovid Therapeutics, Inc. has a consensus price target of $4.05, signalling upside risk potential of 153.06%. On the other hand Cassava Sciences, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 294.09%. Given that Cassava Sciences, Inc. has higher upside potential than Ovid Therapeutics, Inc., analysts believe Cassava Sciences, Inc. is more attractive than Ovid Therapeutics, Inc..

Ovid Therapeutics, Inc. has a beta of 0.254, which suggesting that the stock is 74.621% less volatile than S&P 500. In comparison Cassava Sciences, Inc. has a beta of -0.628, suggesting its less volatile than the S&P 500 by 162.76%.

Ovid Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ovid Therapeutics, Inc. pays -- of its earnings as a dividend. Cassava Sciences, Inc. pays out -- of its earnings as a dividend.

Ovid Therapeutics, Inc. quarterly revenues are $132K, which are larger than Cassava Sciences, Inc. quarterly revenues of --. Ovid Therapeutics, Inc.'s net income of -$12.2M is lower than Cassava Sciences, Inc.'s net income of -$10.8M. Notably, Ovid Therapeutics, Inc.'s price-to-earnings ratio is -- while Cassava Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ovid Therapeutics, Inc. is 17.20x versus 2.69x for Cassava Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.